News
ESSA Pharma to Present at the Bloom Burton & Co. Healthcare Investor Conference
ESSA Pharma Presents Preclinical Data Supporting the Therapeutic Potential of EPI-7386 at the 2021 American Association of Cancer Research
ESSA Announces Change to its Board of Directors
ESSA Pharma Announces Exercise of Option in Connection with Recently Completed $130 Million Financing
ESSA Pharma Inc. Reports Results of Annual General & Special Meeting of Shareholders
ESSA Pharma to Present at Upcoming March Investor Conferences
ESSA Pharma Announces Clinical Collaboration with Astellas to Evaluate the Combination of EPI-7386 and Enzalutamide for Patients with Metastatic Castration-Resistant Prostate Cancer
Essa Pharma Announces Closing of $130 Million Public Offering of Common Stock
ESSA Pharma Announces Pricing of Public Offering of Common Shares
ESSA Pharma Announces Proposed Public Offering of Common Shares